Clinical validation of the Tempus xO assay

Nike Beaubier; Robert Tell; Robert Huether; Martin Bontrager; Stephen Bush; Jerod Parsons; Kaanan Shah; Tim Baker; Gene Selkov; Tim Taxter; Amber Thomas; Sam Bettis; Aly Khan; Denise Lau; Christina Lee; Matthew Barber; Marcin Cieslik; Casey Frankenberger; Amy Franzen; Ali Weiner; Gary Palmer; Robert Lonigro; Dan Robinson; Yi-Mi Wu; Xuhong Cao; Eric Lefkofsky; Arul Chinnaiyan; Kevin P. White

doi:10.18632/oncotarget.25381

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Rapamycin Press LLC dba Impact Journals is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack... This malicious action will be reported to the FBI.

Research Papers:

Clinical validation of the Tempus xO assay

PDF | Full Text | Supplementary Files | How to cite

Oncotarget. 2018; 9:25826-25832. https://doi.org/10.18632/oncotarget.25381

Metrics: PDF 2716 views | Full Text 6563 views

Nike Beaubier1, Robert Tell1, Robert Huether1, Martin Bontrager1, Stephen Bush1, Jerod Parsons1, Kaanan Shah1, Tim Baker1, Gene Selkov1, Tim Taxter1, Amber Thomas1, Sam Bettis1, Aly Khan1, Denise Lau1, Christina Lee1, Matthew Barber1, Marcin Cieslik2, Casey Frankenberger1, Amy Franzen1, Ali Weiner1, Gary Palmer1, Robert Lonigro2, Dan Robinson2, Yi-Mi Wu2, Xuhong Cao2, Eric Lefkofsky1, Arul Chinnaiyan2,3 and Kevin P. White1

1Tempus Labs, Inc., Chicago, Illinois 60654, USA

2Department of Pathology and Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA

3Howard Hughes Medical Institute, Chevy Chase, Maryland 20815, USA

Correspondence to:

Nike Beaubier, email: [email protected]

Kevin P. White, email: [email protected]

Keywords: genomic test; gene panel; cancer; transcriptome; Tempus

Received: August 20, 2017 Accepted: March 21, 2018 Published: May 25, 2018

ABSTRACT

We have developed a clinically validated NGS assay that includes tumor, germline and RNA sequencing. We apply this assay to clinical specimens and cell lines, and we demonstrate a clinical sensitivity of 98.4% and positive predictive value of 100% for the clinically actionable variants measured by the assay. We also demonstrate highly accurate copy number measurements and gene rearrangement identification.

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Papers:

Clinical validation of the Tempus xO assay